Handelsavisen
prelaunch
Companies Healthcare 4891.T
48
4891.T Tokyo Stock Exchange Biotechnology & Medical Research

TMS Co Ltd

¥117,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
-4,2 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

TMS Co Ltd provides healthcare diagnostic services and related research, primarily generating revenue through diagnostic testing and medical research activities.

Business. TMS Co Ltd (4891.T) is a Japanese biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models. Headquartered in Japan, the company is listed on the Tokyo Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target620,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
620,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-4,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4891.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4891.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TMS Co Ltd (4891.T) is a Japanese biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models. Headquartered in Japan, the company is listed on the Tokyo Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    TMS Co Ltd exhibits a highly liquid capital structure, with cash and equivalents amounting to ¥34.18 billion, representing 93.2% of total assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative leverage profile. The current ratio of 51.12 suggests strong short-term liquidity, well above the typical thresholds for financial stability.

    Profitability metrics are negative, with a return on equity of -4.18% and a return on assets of -4.09%. These figures indicate that the company is currently generating losses relative to its equity and asset base. The operating and net income are both negative, at ¥-1.52 billion and ¥-1.49 billion, respectively, signaling a need for operational improvements or cost reductions to achieve profitability.

    The company's revenue is concentrated in its healthcare diagnostics segment, with no disclosed geographic diversification in the provided data. This lack of geographic segmentation suggests potential exposure to regional market risks, particularly in Japan, where the company is headquartered. The absence of detailed segment reporting limits the ability to assess the performance of individual business lines.

    Looking ahead, the company's growth trajectory is uncertain. No specific revenue growth rates or outlooks are provided in the input data, and the current FY outlook does not include numeric deltas. Analysts have assigned a mean price target of ¥620.00, with a strong buy recommendation, but this does not necessarily reflect near-term operational performance.

    Risk factors for TMS Co Ltd include the current unprofitable operations and the potential for future dilution, although the risk assessment indicates that dilution is currently low. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is assessed as low. However, the negative returns on equity and assets suggest that the company may need to raise additional capital in the future, which could lead to share dilution.

    Recent events and filings do not indicate any major corporate actions or strategic shifts. The company's financial snapshot does not include recent earnings call transcripts or 10-K filings, so the narrative is based on the latest available financial data. The lack of recent events or strategic announcements suggests a stable but unremarkable operational environment.

    Key takeaways
    • TMS Co Ltd has a highly liquid balance sheet with no long-term debt and a current ratio of 51.12.
    • The company is currently unprofitable, with negative returns on equity and assets.
    • Revenue is concentrated in the healthcare diagnostics segment, with no geographic diversification disclosed.
    • Analysts have assigned a strong buy rating, but the company's operational performance remains a concern.
    • The risk of dilution is currently low, but the company may need to raise capital in the future to address its losses.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2025-10-15
    Q3 2025 · Quarter highlights

    Operating income +42,3% YoY; Net income +42,2% YoY.

    Revenue
    Operating income-¥226.5M+42,3 % YoY
    Net income-¥228.6M+42,2 % YoY
    Free cash flow
    EPS
    Operating cash flow
    Financials
    Income statement
    Revenue
    Gross profit
    Operating income-¥226.5M
    Net income-¥228.6M
    Highlights
    • Operating income +42,3% YoY
    • Net income +42,2% YoY

    Valuation FY

    Market price
    ¥117,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥3.57B
    Net cash
    ¥3.42B
    Current ratio
    51.1
    Debt / equity
    0.0
    ROA
    -4.1%
    ROE
    -4.2%
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -25,00
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-25 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-25,00
    Revenueno estimateno estimate0 JPY
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in JPY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy1
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price target¥620,00 · Median ¥620,00
    Low ¥620,00High ¥620,00
    EPS surprise
    +34,5 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥620,00
    Mean¥620,00
    Median¥620,00
    High¥620,00
    Spot¥117,00
    +429.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-4,2 %Above median
    D/E0,00Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Return On Assets
      net_income / total_assets
    Source documents
    • TMS Co Ltd Market data — financials · 2026-05-26
    • TMS Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4891.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2025-10-15 12:00 UTCEARNINGSQuarterly results — Q3 2025 Net JPY -228.6M
    2025-07-15 12:00 UTCEARNINGSQuarterly results — Q2 2025 Net JPY -201.1M
    2024-04-12 11:30 UTCEARNINGSAnnual results — FY 2024 Net JPY -960.0M
    2023-04-14 11:30 UTCEARNINGSAnnual results — FY 2023 Net JPY -860.9M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage